Current Research Studies

The Family Allergy & Asthma Research Institute is currently recruiting individuals who have allergic and asthmatic conditions for our active studies listed below. You do not need to be a current patient of Family Allergy & Asthma to participate in a research study.

If you are interested in participating and believe you meet the requirements, please contact our research staff to learn more at 502.368.0732.

Severe Uncontrolled Asthma Study

The main purpose of this study is to test if the study drug, tezepelumab, is effective in treating severe asthma and whether it causes any side effects.  Tezepelumab will be compared with placebo.  The study is open to patients with severe uncontrolled asthma ages 12 – 80.

Study Duration:
The study will last 69-71 weeks, and there will be up to 19 visits at the clinic.

If interested in participating in this clinical study, call: 502.368.0732

Request More Information About This Study

Atopic Dermatitis Research Study

The main purpose of this study is to test if the study drug, tralokinumab, is better than a placebo at treating moderate to severe atopic dermatitis (a type of eczema) in adolescents between the ages of 12 to 17 years.

Study Duration:
The study will last up to 72 weeks, and there will be up to 30 visits at the clinic and 2 telephone contacts by the study staff. The visits at the clinic will typically be every second week.  There will be a possibility for transfer to known treatment of tralokinumab after 16 weeks if no response to study treatment in the previous 16 weeks.

If interested in participating in this clinical study, call: 502.368.0732

Request More Information About This Study

Asthma Study

Location: Louisville
Description: A 52 week, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma.
Requirements: Ages 12 and up.

  • Diagnosis of asthma for 24 months prior to enrollment.
  • Must be on high dose ICS with LABA for at least 3 months prior to screening.
  • FEV1 > 40% and <80% Reversibility of >12% and 200ml within 2 years of screening.
  • History of 2 or more asthma exacerbations within 12 months prior to screening.
  • Non-smokers or previous smokers with >10 pack year.

Exclusion: Cannot have had an asthma exacerbation requiring systemic steroids or ER visit within 6 weeks prior to screening.

Request More Information About this Study

Severe Eosinophilic Asthma Study

Location: Louisville
Description: Observational study to evaluate effectiveness of NUCALA and to describe the use of NUCALA in real world clinical practice to provide a more complete understanding of the value of NUCALA for patients with severe eosinophilic asthma. No special tests or examinations are needed. 2 year study in which patients receive usual care from their doctor. Participants will complete questionnaires no more frequently than 3 months that take about 5 minutes to complete.
Requirements: Adults, ages 18 years or over.

  • Patient must have been diagnosed with asthma.
  • Have Anthem Insurance.
  • Physician decision to start NUCALA
  • Allow medical records to be obtained from past 12 months.

Exclusion: NUCALA injections in the past 12 months, can not have participated in another clinical trial in the past 12 months.

Request to Learn More About This Research Study

Interested in hearing more about these Research Trials?

Please contact one of our staff at 502.368.0732 or fill out the form below:

  • This field is for validation purposes and should be left unchanged.